.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Ravulizumab is a long-acting complement C5 inhibitor designed to reduce the interval burden of treatment compared with eculizumab. Final open-label extension data from the phase 3 CHAMPION MG programme followed adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis for up to four years. Sustained improvements were observed in MG-ADL, quantitative myasthenia measures, quality of life and fatigue. Corticosteroid use also declined during the extension period, and clinical deterioration events were reduced compared with the earlier placebo period. The results support durable efficacy of complement inhibition in AChR-positive generalized MG. Because the extension was open-label, it is not equivalent to a long-term randomized comparison, but it provides useful information about persistence of benefit and safety. For HCPs, ravulizumab is most relevant to patients with generalized MG whose disease remains functionally burdensome despite standard therapy. Vaccination and infection-risk management are essential with complement inhibition, and cost and dosing logistics also influence practical use. The study fits IANCON's focus on myasthenia gravis and the expanding role of targeted immune therapies.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Ravulizumab is a long-acting complement C5 inhibitor designed to reduce the interval burden of treatment compared with eculizumab. Final open-label extension data from the phase 3 CHAMPION MG programme followed adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis for up to four years. Sustained improvements were observed in MG-ADL, quantitative myasthenia measures, quality of life and fatigue. Corticosteroid use also declined during the extension period, and clinical deterioration events were reduced compared with the earlier placebo period. The results support durable efficacy of complement inhibition in AChR-positive generalized MG. Because the extension was open-label, it is not equivalent to a long-term randomized comparison, but it provides useful information about persistence of benefit and safety. For HCPs, ravulizumab is most relevant to patients with generalized MG whose disease remains functionally burdensome despite standard therapy. Vaccination and infection-risk management are essential with complement inhibition, and cost and dosing logistics also influence practical use. The study fits IANCON's focus on myasthenia gravis and the expanding role of targeted immune therapies.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
